Xeris Biopharma Holdings, Inc.

NASDAQ:XERS

Biotechnology

Healthcare
$16.99 +0.58%

+$0.04 today

Market cap
$3.10B
Beta
0.90
P/E (TTM)
98.7
EPS (TTM)
$0.07
52W Low $4.40High $10.08

Volume 2.76M

Average 1.66M

XERS Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Xeris Biopharma Holdings, Inc.NASDAQ: XERS

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation dips below year-ago levels

Q1 FY2026 stock-based compensation of $4.14M fell 6.8% year over year, behind the +15.9% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 21.5% from the prior quarter. Over 3 fiscal years it compounded at +22.5% a year.

Context

  • Stock-based compensation amounted to 7.7% of revenue in FY2025, down 1.4 pp from a year earlier.
  • Stock-based compensation increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -6.8% toward the trailing-twelve-month pace of +15.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$4.14M-21.5% QoQ
Last fiscal yearDec 2025
$22.37M+21.8% YoY
LTMMar 2026
$22.06M+15.9% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-6.8%——
1 year+21.8%——
3-year CAGR+22.5%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
22.37M USD
Year-over-year change
+21.8%
4-year CAGR
+18.4%

Stock-Based Compensation vs competitors

How XERS compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +15.9% is the 4th highest of 9, against a peer median of -34.4%.
  • Stock-based compensation amounts to 7.0% of revenue for XERS, versus a peer median of 4.0%.
XERS Competitors
Stock-Based Compensation for XERS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MBXMBX Biosciences, Inc. Common StockLTM Sep 2026$41.75M USD+456.0%+204.9%—
XERSXeris Biopharma Holdings, Inc.LTM Mar 2026$22.06M USD+15.9%+22.5%7.0%
SEPNSepterna, Inc.LTM Sep 2026$19.67M USD+177.6%+77.3%20.4%
MNKDMannKind CorporationLTM Mar 2026$14.49M USD-36.6%—4.0%
CORTCorcept Therapeutics IncorporatedLTM Jun 2026$11.27M USD-119.6%+25.8%1.4%
ETONEton Pharmaceuticals, Inc.LTM Mar 2026$5.83M USD+64.5%+9.3%6.7%
SPRBSpruce Biosciences, Inc.LTM Mar 2026$2.72M USD-37.2%-10.8%—
GHRSGH Research PLCLTM Mar 2026$1.88M USD-32.3%——
ASNDAscendis Pharma A/SLTM Sep 2026€0 EUR-100.0%—0.0%
Peer median (excluding XERS) —-34.4%+25.8%4.0%

Competitors are the stored peer set for XERS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(122.73M)(94.66M)(62.26M)(54.84M)554K
Depreciation & Amortization1.88M12.67M13.16M12.63M12.16M
Deferred Income Tax(1.42M)(1.42M)(1.25M)(2.27M)0
Stock-Based Compensation11.38M12.16M10.72M18.36M22.37M
Change in Working Capital11.85M(35.15M)(6.29M)(8.82M)(10.36M)
Accounts Receivables(13.37M)(13.37M)(8.37M)(1.22M)(10.64M)
Inventory(7.47M)(7.47M)(14.8M)(8.78M)(19.29M)
Accounts Payables(4.32M)(4.32M)6.96M(9.61M)(69K)
Other Working Capital19.98M(9.99M)9.92M10.79M19.63M
Other Non-Cash Items3.5M3.52M(1.1M)(2.05M)3.91M
Operating Cash Flow(102.89M)(102.89M)(47.02M)(36.98M)28.63M
Capital Expenditures(524K)(524K)(2.26M)(868K)(696K)
Acquisitions (Net)38.47M0000
Purchases of Investments(43.02M)0(43.74M)(34.49M)0
Sales of Investments34.99M34.99M40M40.24M0
Other Investing Activities4.55M0000
Investing Cash Flow34.46M34.46M(6M)4.88M(696K)
Debt Repayment0102.72M038.17M9.17M
Common Stock Issued27M30M581K013.1M
Common Stock Repurchased(534K)(468K)(1.01M)(3.73M)(10.88M)
Dividends Paid00000
Other Financing Activities0(4.78M)(604K)1.73M0
Financing Cash Flow27.25M127.47M(1.61M)36.17M11.39M
Effect of Forex Changes(3K)(4.35M)000
Net Change in Cash59.04M59.04M(54.64M)4.07M39.32M
Free Cash Flow(103.42M)(103.42M)(49.29M)(37.85M)27.93M

Xeris Biopharma Holdings, Inc.

NASDAQ:XERS

Intrinsic Alpha fair value

Locked

Current Price

$16.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.